MedPath

Osaka study of Nicorandil effect on Chronic Kidney Disease

Not Applicable
Conditions
Chronic kidney disease Ischemic coronary disease
Registration Number
JPRN-UMIN000001508
Lead Sponsor
Osaka University School of Medicine Department of Nephrology
Brief Summary

Association with BNP reduction was observed.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
19
Inclusion Criteria

Not provided

Exclusion Criteria

(1)Liver cirrhosis (2)Previous organ transplantation (3)Administered anti-cancer drugs within 2 years (4)Non Japanese (5)Known HIV/AIDS

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Endothelial function measured by reactive hyperemia by pulse amplitude tonometry (RH-PAT) and augmentation index and cardiac stress marker.
Secondary Outcome Measures
NameTimeMethod
The primary end point is death from all causes, morbidity and mortality from cardiovascular causes, a composite of myocardial infarction, stroke, first hospitalization for heart failure or unstable angina, coronary or peripheral revascularization, or death from cardiovascular causes. The time to the first event of the composite end point of a doubling of the serum creatinine concentration, end-stage renal disease, or death is also set as a primary end point.
© Copyright 2025. All Rights Reserved by MedPath